# EDGAR Filing Document

**Accession Number:** 0001782999
**File Stem:** 0001193125-23-058242
**Filing Date:** 2023-3
**Character Count:** 8082
**Document Hash:** 9248f90773c6fb12b6ddbe5510823a7d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-058242.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001193125-23-058242

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230302

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PureTech Health plc
- **CENTRAL INDEX KEY:** 0001782999
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39670
- **FILM NUMBER:** 23699504

**BUSINESS ADDRESS:**
- **STREET 1:** 6 TIDE STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-482-2333

**MAIL ADDRESS:**
- **STREET 1:** 6 TIDE STREET
- **STREET 2:** SUITE 400
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**Report of Foreign Private Issuer** 

**Pursuant to Rule 13a-16 or 15d-16** 

**under the Securities Exchange Act of 1934** 

**For the month of February, 2023** 

**Commission File Number 001-39670** 

------

## PURETECH HEALTH PLC
**(Translation of registrant's name into English)** 

------

**6 Tide Street, Suite 400** 

**Boston, Massachusetts 02210** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K** 

On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the "Company") announced the commencement of a $50 million share repurchase program (the "Program") of its ordinary shares of one pence each ("Ordinary Shares"). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited ("Jefferies") in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company's general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 15, 2022, Chapter 12 of the Financial Conduct Authority's UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended February 28, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date** | **Ordinary Shares<br>Repurchased** | **Volume Weighted<br>Average Price Paid<br>per Ordinary Share** | **Highest Price Paid** | **Lowest Price Paid** |
|  February 1, 2023 | 10347 | 251.59p | 256.00p | 247.00p |
|  February 2, 2023 | 8053 | 255.94p | 265.00p | 249.50p |
|  February 3, 2023 | 5042 | 262.88p | 265.00p | 261.00p |
|  February 6, 2023 | 10587 | 260.55p | 265.00p | 258.00p |
|  February 7, 2023 | 10824 | 253.92p | 261.00p | 249.00p |
|  February 8, 2023 | 10549 | 248.18p | 255.00p | 244.50p |
|  February 9, 2023 | 10356 | 252.51p | 255.50p | 248.00p |
|  February 10, 2023 | 10153 | 241.67p | 247.00p | 238.50p |
|  February 13, 2023 | 10308 | 237.28p | 240.00p | 235.00p |
|  February 14, 2023 | 10499 | 233.06p | 235.50p | 230.00p |
|  February 15, 2023 | 9522 | 234.34p | 237.50p | 231.00p |
|  February 16, 2023 | 10386 | 232.49p | 235.50p | 230.00p |
|  February 17, 2023 | 10713 | 232.91p | 234.00p | 230.50p |
|  February 20, 2023 | 10728 | 228.38p | 232.00p | 227.00p |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  February 21, 2023 | 10196.0 | 229.42p | 232.50p | 223.00p |
|  February 22, 2023 | 10344.0 | 218.21p | 222.00p | 215.50p |
|  February 23, 2023 | 10788.0 | 217.65p | 219.50p | 216.00p |
|  February 24, 2023 | 11729.0 | 223.91p | 226.50p | 218.50p |
|  February 27, 2023 | 11631.0 | 224.64p | 227.00p | 218.50p |
|  February 28, 2023 | 12113.0 | 227.22p | 229.00p | 225.50p |

---

During the month ended February 28, 2023, the Company repurchased an aggregate of 204,868 Ordinary Shares. As of February 28, 2023, the Company's issued share capital was 289,468,159 shares, 10,807,414 of which were held in treasury, resulting in total voting rights in the Company of 278,660,745 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

February 1, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4661879.html</u>

February 2, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4663341.html</u>

February 3, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4664663.html</u>

February 6, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4666154.html</u>

February 7, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4667560.html</u>

February 8, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4669020.html</u>

February 9, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4670406.html</u>

February 10, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4671750.html</u>

February 13, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4673189.html</u>

February 14, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4674642.html</u>

February 15, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4675976.html</u>

February 16, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4677518.html</u>

February 17, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4678907.html</u>

February 20, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4680373.html</u>

February 21, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4681594.html</u>

February 22, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4683029.html</u>

February 23, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4684454.html</u>

February 24, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4685861.html</u>

February 27, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4687469.html</u>

February 28, 2023: <u>https://data.fca.org.uk/artefacts/NSM/RNS/4689464.html</u>

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | PURETECH HEALTH PLC | PURETECH HEALTH PLC | PURETECH HEALTH PLC |
| Date: March 2, 2023 | By: | /s/ Daphne Zohar | /s/ Daphne Zohar |
|  |  | Name: | Daphne Zohar |
|  |  | Title: | Chief Executive Officer |

---